文献速递妇科产科

外阴上皮内瘤变或外阴癌手术后宫颈与阴道不典型增生的风险:一项6年随访研究

Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study.
PubMed 文献 · Gynecol Oncol · 2019-07-30

该回顾性研究纳入2006至2014年间因高级别外阴上皮内瘤变(VIN)或外阴癌接受手术的302例女性,中位随访72个月,评估术后细胞学筛查异常及高级别不典型增生的频率,并分析既往子宫切除术是否降低风险。结果显示25%患者细胞学异常,高级别病变风险为8%,既往子宫切除术未显著降低高级别细胞学风险(OR 0.87,95%CI 0.5-1.6)。作者建议术后至少6-12个月进行细胞学筛查。

要点

  • VIN或外阴癌术后患者高级别不典型增生风险为8%。
  • 既往子宫切除术未显著降低高级别细胞学风险(OR 0.87)。
  • 作者建议术后至少6-12个月进行细胞学筛查。

核心结论

  • 因VIN或外阴癌手术治疗的女性通过监测筛查发生至少高级别不典型增生的风险为8%,且既往子宫切除术不降低该风险。
  • 作者根据现有指南外推,推荐术后至少6-12个月进行监测细胞学筛查。

研究设计与样本

  • 回顾性识别2006年至2014年间因高级别VIN或外阴癌接受手术的女性,包括因任何指征行既往子宫切除术的患者。
  • 采用单因素和多因素逻辑回归分析VIN和外阴癌手术后细胞学异常的临床相关因素。
  • 共302例女性接受外阴手术后细胞学筛查监测,其中99例(33%)有既往子宫切除术。

主要发现

  • 中位随访72个月,75例(25%)女性细胞学结果异常;其中47例(63%)为低级别,28例(37%)为高级别,包括2例(3%)浸润性癌。
  • 高级别阴道上皮内瘤变(VAIN)、宫颈上皮内瘤变(CIN)或癌症的发生率在既往子宫切除术后无显著差异(VAIN 2+为9%,CIN 2+为7%)。
  • 多因素分析显示,VIN或外阴癌治疗后高级别细胞学的相关因素包括非白人种族(OR 3.6,95%CI 1.7-7.8)、既往细胞学异常(OR 3.5,95%CI 1.6-7.6)和免疫缺陷(OR 3.4,95%CI 1.3-8.8)。
  • 既往子宫切除术未显著降低高级别细胞学风险(OR 0.87,95%CI 0.5-1.6)。

关键数值与推荐

  • 高级别细胞学定义为高级别不典型增生,包括VAIN 2+、CIN 2+或癌症。
  • 非白人种族OR 3.6(95%CI 1.7-7.8)、既往细胞学异常OR 3.5(95%CI 1.6-7.6)、免疫缺陷OR 3.4(95%CI 1.3-8.8)与高级别细胞学相关。
  • 既往子宫切除术OR 0.87(95%CI 0.5-1.6),未显著降低高级别细胞学风险。
  • 作者推荐术后至少6-12个月进行监测细胞学筛查。

临床怎么用

  • 作者建议对VIN或外阴癌手术治疗后的女性,在术后至少6-12个月进行细胞学筛查监测。
  • 既往子宫切除术不降低高级别细胞学风险,不应因此省略监测。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the frequency of abnormal surveillance cytology leading to high-grade dysplasia after surgical management for high-grade vulvar intraepithelial neoplasia (VIN) and vulvar cancer and to determine whether prior hysterectomy reduces this risk. METHODS: Women who underwent surgery for high-grade VIN or vulvar cancer between 2006 and 2014 were identified retrospectively. Patients who underwent prior hysterectomy for any indication were included. Univariate and multivariate logistic regression analyses were used to identify clinical correlates of abnormal cytology after surgical treatment for VIN and vulvar cancer. RESULTS: During a median follow-up for 72 months, 302 women underwent surveillance with cytologic screening after vulvar surgery including 99 (33%) women with prior hysterectomy. 75 (25%) women had abnormal cytology results. Of those, 47 (63%) were low-grade and 28 (37%) were high-grade, including 2 (3%) cases of invasive cancer. The rates of high-grade vaginal intraepithelial neoplasia (VAIN), cervical intraepithelial neoplasia (CIN), or cancer were not significantly different despite prior hysterectomy (9% VAIN 2+, 7% CIN 2+). Multivariate analysis showed that correlates of high-grade cytology following treatment for VIN or vulvar cancer included non-white race [odds radio (OR) 3.6, 95% confidence interval (CI) 1.7-7.8], prior abnormal cytology (OR 3.5, 95% CI 1.6-7.6), and immunodeficiency (OR 3.4, 95% CI 1.3-8.8). Prior hysterectomy did not significantly decrease risk of high-grade cytology (OR 0.87, 95% CI 0.5-1.6). CONCLUSIONS: Women treated surgically for VIN/vulvar cancer have an 8% risk of at least high-grade dysplasia from surveillance screening and prior hysterectomy does not mitigate the risk. Extrapolating from current guidelines, we recommend surveillance cytology screening at least 6-12 months after treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Buchanan TR, Zamorano AS, Massad LS, et al. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study. Gynecol Oncol. 2019. PMID: 31375270. doi:10.1016/j.ygyno.2019.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。